ArticleLeukemia2025
Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variants.
Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom.British journal of haematology · 2026Article
- Rosai-Dorfman disease withOxford medical case reports · 2026Article
- Case Report: Erdheim-Chester disease presenting as abdominal cocoon syndrome.Frontiers in immunology · 2026Article
- The xanthogranuloma family of histiocytic neoplasms in the molecular era: Erdheim-Chester disease and beyond.Hematology. American Society of Hematology. Education Program · 2025Review
- Histiocyte Society blueprint for non-Langerhans cell histiocytosis research: unraveling complex diseases through collaboration.Haematologica · 2025Review
- Multifocal sclerotic lesions in Erdheim-Chester disease successfully treated with tocilizumab.Immunotherapy · 2025Article
- Molecular profiling is critical to guide MEK inhibitor use in Erdheim-Chester disease.Leukemia · 2025Article
- MEK inhibitors are effective in Erdheim-Chester disease regardless of MAPK pathway mutations.Leukemia · 2025Article
- Article
- Erdheim-Chester Disease in Adults: 11 Cases from a Canadian Rare Diseases Program.Clinical hematology international · 2025Article
- Unraveling cutaneous histiocytosis: insights into histology, pathogenesis, diagnosis, and treatment pitfalls.Frontiers in medicine · 2025Review
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.